Double-blind crossover trial of gabapentin in SPG4-linked hereditary spastic paraplegia

Eur J Neurol. 2007 Jun;14(6):663-6. doi: 10.1111/j.1468-1331.2007.01812.x.

Abstract

Patients with hereditary spastic paraplegia (HSP) are often treated with antispastic drugs to relieve symptoms but documentation is lacking. In this study, gabapentin was tested in a double-blind crossover trial on a group of patients with HSP and linkage to the SPG4 locus. There was no difference between periods with gabapentin and placebo treatment in clinical assessment, self-reported parameters or paired transcranial magnetic stimulation evaluation of motor cortical excitability.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / genetics*
  • Adult
  • Aged
  • Amines / therapeutic use*
  • Anticonvulsants / therapeutic use*
  • Cross-Over Studies
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Double-Blind Method
  • Female
  • Gabapentin
  • Humans
  • Male
  • Middle Aged
  • Spastic Paraplegia, Hereditary / drug therapy*
  • Spastic Paraplegia, Hereditary / genetics*
  • Spastin
  • Statistics, Nonparametric
  • gamma-Aminobutyric Acid / therapeutic use*

Substances

  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Adenosine Triphosphatases
  • Spastin
  • SPAST protein, human